FDA Inspection 1079961 — Hikma Pharmaceuticals USA, Inc.
The FDA completed an inspection of Hikma Pharmaceuticals USA, Inc. on Feb 1, 2019 in Eatontown, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 1, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Eatontown, NJ (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)